Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2003-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a potential generic 250 mg
clarithromycin tablet formulation compared with Abbott Laboratories 250 mg clarithromycin
tablet, Biaxin® following a single 250 mg dose, administered in the fasted state.